Facebook Pixel

New HPV Test to Determine High Risk for Cancer

Rate This
Cervical Cancer related image Photo: Getty Images

On April 20, 2011 Roche Diagnostics announced the United States Food and Drug Administration approved of its new HPV test, cobas. This new test detects the presence of DNA for 14 high risk strains of the virus. There are a few differences however between cobas and the other HPV tests currently on the market.

Roche’s test will check for 14 of the high risk HPV strains. The Hologic test, Cervista, also tests for these same 14 strains, while the digene test checks for 13.

Once this is completed, the Roche test will then concurrently genotype the specimen for HPV types 16 and 18. These two HPV strains are shown to cause approximately 70 percent of all cervical cancers.

The ATHENA study was utilized to determine the effectiveness of this new cobas test. The study was conducted throughout the United States and involved a total of 47,000 women. It showed that one in 10 women who tested positive for types 16 and 18 genotyping had precancerous lesions despite having a negative result on their Pap smears.

Roche representatives Christoph Majewski , Head of HPV molecular science and Dr. Catherine Behrens, Director of Medical Affairs, stated that of the women involved in the ATHENA study with a Pap result of ASCUS (atypical squamous cells of undetermined significance), 90 percent were shown on biopsy to have CIN2/3 lesions. Of those, 46 percent were CIN3.

The National Cancer Institute indicated that 10 percent of women who are positive for HPV types 16 and 18 have been shown to develop CIN3 (cervical intraepithelial neoplasia grade 3) within three years. CIN3/CIS (carcinoma in situ) is the most severe type of abnormality prior to the lesion becoming an invasive cancer.
The current digene HPV test in existence for over ten years does not, at this point, genotype within its 13 panel assay. It has, however, since its inception performed over 40 million tests and had over 300 peer review articles with respect to its methods. Both Hologic and Roche has a bit of catching up to do in that respect.

Add a Comment1 Comments

EmpowHER Guest

I myself have had genital herpes for almost 2 years now. Once I broke up with the person I got it from, I felt like I had to navigate the waters all by myself.I have to say that http://www.herpespal.com has been a blessing, its great being able to talk to other people in the same situation. I personally have found peace and happiness. If you haven’t, you will. Ignoranceand denial is not the solution. Be informed… Learn the truth… Here. Which has more than 680000 memebers according some news and it have provided many services such as chatting,blogs,test center,forum etc. I am still glad that I had the opportunity to confirm that having Herpes doesn't have to be a limitation.

May 3, 2011 - 8:26am
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy
Add a Comment

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.

Cervical Cancer

Get Email Updates

Related Checklists

Cervical Cancer Guide

HERWriter Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!